Key result
Protocol describes rationale for screening Fabry disease in obstructive HCM patients undergoing surgical myectomy.
Why the study?
Fabry disease can mimic obstructive hypertrophic cardiomyopathy and may be misdiagnosed, leading to potentially unnecessary aggressive treatments.
Observational
May warrant targeted Fabry screening in unexplained hypertrophy; leaves open enzyme replacement benefit in isolated cardiac forms.
Exogenous administration of the deficient enzyme has been shown to clear microvascular endothelial deposits, which are integral to disease manifestation, in the kidney, skin, and heart. Interestingly, isolated cardiac Fabry disease may exist without other overt manifestations. In one study, 3% of male subjects with myocardial hypertrophy were found to harbour this enzyme deficiency, 3 whereas another study showed that approximately 4% of patients referred to a tertiary centre for evaluation of HCM actually had evidence of Fabry disease. 4 If this storage disease were misdiagnosed as HCM, patients who could be treated effectively with medication might be subjected to aggressive procedures such as septal ablation or surgical septal myectomy. We sought to determine the frequency of Fabry disease among patients who underwent surgical myectomy for the relief of symptomatic obstructive HCM.
No takes yet. Share an insight, caveat, or question.
Steve R. Ommen (2003) conducted an observational in Obstructive hypertrophic cardiomyopathy. Fabry disease was evaluated on Frequency of Fabry disease. The abstract outlines the rationale for determining the frequency of Fabry disease among patients undergoing surgical myectomy for obstructive hypertrophic cardiomyopathy, but no results are reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: